15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Acurx Pharmaceuticals LLC, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $31.00 to $31.00, so the covering firms are broadly aligned. The average target of $31.00 sits 2083% above the current $1.42. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.44 next quarter toward $-1.75 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Acurx Pharmaceuticals LLC.
As of Aug, 1 of 1 firms rate ACXP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ACXP EPS & revenue forecast
EPS · NEXT QUARTER
$-0.44
Range $-0.47 – $-0.41 · 2 analysts · +42% YoY
Next period, 2 analysts expect Acurx Pharmaceuticals LLC to earn $-0.44 a share (range $-0.47 – $-0.41), versus $-0.31 a year earlier. Full-year consensus is $-1.93, growing to $-1.75 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Acurx Pharmaceuticals LLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACXP.
#1
Ed Arce
HC Wainwright & Co. · Rank #127
Buy
$12.00+745.1% to target
Overall win rate
44%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #417
Buy
$10.00+604.2% to target
Overall win rate
33%
+ Follow
#3
James Molloy
Alliance Global Partners · Rank #445
Buy
$10.00+604.2% to target
Overall win rate
25%
+ Follow
#4
MK
Matthew Keller
HC Wainwright & Co.
Buy
$31.00+2083.1% to target
Coverage
—
+ Follow
#5
MK
Matthew Kelsey
HC Wainwright & Co.
Buy
$8.00+463.4% to target
Coverage
—
+ Follow
ACXP stock forecast FAQ
What is ACXP's average 12-month price target?+
The 1 analysts with a live target average $31.00 for Acurx Pharmaceuticals LLC over the next 12 months, ranging from a $31.00 high to a $31.00 low.
Is ACXP stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover ACXP?+
1 analysts have an active rating on Acurx Pharmaceuticals LLC, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering ACXP?+
Among analysts who currently cover ACXP, Ed Arce of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #127). Their current call is Buy with a $12.00 target.
What is Acurx Pharmaceuticals LLC's projected EPS for next quarter?+
The consensus estimate is $-0.44 per share (range $-0.47 – $-0.41) across 2 analysts. Full-year EPS is projected at $-1.93, rising to $-1.75 the following year.
How much revenue is Acurx Pharmaceuticals LLC expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ACXP lately?+
As of Aug, 1 of 1 firms rate ACXP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACXP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
